Positive results with Vismodegib and basal cell carcinoma

Carcinoma Basocelular TratamientoEl cancer basocelular is one of the most serious skin cancer that exist and a sore prediction in patients, since it is capable of advanced cancer of degeneration or distortion and with few therapeutic alternatives.
Barely a few days, laboratories Genentech Roche Group announced positive results of your last Phase II clinical trial for basal cell carcinoma (CBC) inhibitor using a drug that controls the development and growth of tumor cells in early: the vismodegib.

El vismodegib acts on a receptor-like protein called smoothened and linked to the ruta Hedgehog y al oncogen SMO. This route, disproportionately activated due to a mutation of SMO, may lead to the growth of cancer cells that originate basal cell carcinoma. El vismodegib has demonstrated its ability to control and inhibit these signals when there is a mutation resulting in unregulated activation of the Hedgehog route. De momento, The test was successfully conducted in people with carcinoma operable and oral administration is.

Sources: Gene.com, EuropaPress

Info: http://www.selleckchem.com/products/GDC-0449.html

3 Comments positive results with Vismodegib and basal cell carcinoma
  1. doktor9 says:

    As news highlights, In the USA the FDA has approved laboratories-Myers Squibb Brystol ipilimumab, a new drug that prolongs life until 4 months in patients suffering from advanced melanoma. It warns of possible adverse reactions in the immune system.

  2. administrator says:

    The FDA has approved Roche's marketing Vismodegib for patients with basal cell carcinoma in advanced stage. Will be given in cases where the tumor can not be treated with surgery or radiotherapy. Basal cell carcinoma is curable while reestringido, pere sometimes can spread to surrounding tissues and can affect organs. The PDF of the press release can be found here publicly: http://www.roche.com/med-cor-2011-11-09-sp.pdf

  3. administrator says:

    THE PDF refers to the application for approval. Here the news 30 of January of 2012: http://www.roche.com/media/media_releases/med-cor-2012-01-30.htm

Deja tu comentario
Your Comment